Alex Carchidi is a Writer and Entrepreneur at The Motley Fool. He specializes in finance and investment topics, particularly focusing on cryptocurrency, blockchain, and personal finance, drawing on his background in the biotech industry to inform his analyses. Alex's work has been featured in Nasdaq, Yahoo News, Yahoo Finance, USA TODAY, and other prominent outlets.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Alex Carchidi's coverage predominantly focuses on investment analysis within the healthcare and pharmaceutical sectors, particularly gene-editing companies and biotech stocks. His articles often cite data to support his analyses.
To effectively engage Alex, provide pitches that offer in-depth insights into investment opportunities or risks within the healthcare and pharmaceutical industries. Experts with a deep understanding of gene-editing technologies, biotech stocks, and pharmaceutical companies may find success by offering valuable perspectives for inclusion in his articles.
Given that Alex does not have a specific geographic focus mentioned, sources from any location who possess relevant expertise in these areas could potentially be suitable for engagement.
This information evolves through artificial intelligence and human feedback. Improve this profile .
There's one area in particular where both XRP and Ethereum are struggling to justify their value.
By: Alex Carchidi
This crypto exchange is giving investors a form of exposure to SpaceX before its IPO.
By: Alex Carchidi
Every performance metric needs to be evaluated in its proper and full context. Once in a great while, the best-looking numbers are the ones investors should worry about the most.
By: Alex Carchidi
The coin is becoming less volatile as it matures, and that's causing some people to question its value.
By: Alex Carchidi
The rocket company has held the coin for a handful of years.
By: Alex Carchidi
The market's appetite for exposure to the cryptocurrency is strong.
By: Alex Carchidi
Biotech companies have always licensed programs, but never so many from one region in particular.
By: Alex Carchidi
If privacy coins are the future, the future will belong to those who buy them soon.
A few different players are taking an interest in the network.
By: Alex Carchidi
This little-discussed pipeline program could prove to be a big success. Many investors who follow CRISPR Therapeutics CRSP still treat it as a gene-editing story.
